Clinically and ethically relevant questions are related to patient safety, therapeutic efficacy, equitable access, and global governance over humanity’s genetic legacy.
AMA J Ethics. 2019;21(12):E1079-1088. doi:
10.1001/amajethics.2019.1079.
A look at current literature and work by a statewide initiative can motivate development of policies that help respond to unrepresented patients’ needs.
AMA J Ethics. 2019;21(7):E611-616. doi:
10.1001/amajethics.2019.611.
Jonathan Alhalel, Nicolás Francone, Sharon Post, Catherine A. O’Brian, PhD, and Melissa A. Simon, MD, MPH
Underrepresentation of individuals with limited English proficiency who speak Spanish is ongoing in phase 3 biomedical clinical trials and exacerbates health inequity.
AMA J Ethics. 2022;24(4):E319-325. doi:
10.1001/amajethics.2022.319.
John Timothy Kayiwa, MSc, Benard Matovu, MS, Michael Mutebi, Charity Angella Nassuna, MSc, Leonara Nabatanzi, Kevin T. Castle, DVM, MS, Robert M. Kityo, PhD, MS, and Rebekah C. Kading, PhD, MS
Bats are diverse mammals, globally distributed and ecologically critical, yet some carry disease agents that have severe consequences for human health.
AMA J Ethics. 2024;26(2):E153-161. doi:
10.1001/amajethics.2024.153.